Santhera secures runway with Biovail deal for fipamezole
This article was originally published in Scrip
Executive Summary
Biovail has acquired the US and Canadian rights to develop and commercialise Santhera Pharmaceuticals' JP-1730/fipamezole for the treatment of dyskinesia in Parkinson's disease.